| Similar Articles |
|---|
 |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more?   |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
July 28, 2011
Brian Orelli |
But, But, But, I Thought You Were for Sale? BioSante raises cash -- guess it's not on the market. |
The Motley Fool
July 1, 2011
Brian Orelli |
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
August 15, 2011
Brian Orelli |
Another Partner, but Still No Data Sequenom signs up a European partner. |
The Motley Fool
December 15, 2011
Anders Bylund |
BioSante Pharmaceuticals' Shares Died: What You Need to Know Is this meaningful, or just another movement for BioSante Pharmaceuticals? |
The Motley Fool
November 16, 2011
David Williamson |
3 Biotechs Beating the Market The daily health-care news investors need to read. |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development. |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
May 14, 2007
Brian Lawler |
Biosante's Lame Deal Last week, shares of the drugmaker were up 8% after the company announced that it had signed a drug development deal with a tiny European pharma, Pantarhei. |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
June 10, 2009
Brian Orelli |
Up 58% on No News? What's Going On? There's no concrete reason for the massive increase in Sequenom yesterday. The stock was flat until noon, then it steadily climbed up to the moon in afternoon trading. |
The Motley Fool
April 30, 2009
Brian Orelli |
How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome. |
The Motley Fool
January 29, 2008
Brian Lawler |
BioSante's Gamble Against Generics BioSante releases more information on the pivotal studies for its lead drug. |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
The Motley Fool
July 20, 2010
Jordan DiPietro |
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers. |
